SAN DIEGO, Dec. 2, 2015 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
CEO and President Punit Dhillon will
present a corporate overview at Investment Community Visibility
(ICV) Manhattan on Tuesday, December 8, 2015 in New York City. The presentation is scheduled
to begin at 1:45 PM ET at the
Mandarin Oriental Hotel.
ICV Manhattan provides a platform for approximately 50 chief
executives at innovative growth companies to meet and share ideas
with members of ICV's investment community. This two-day event will
allow family office and fund investors to capitalize on new ideas
and businesses that are shaping the future of traditional
industries. In addition to company presentations, experts will
discuss the current landscape of their respective fields through
participation in thought leader panels and roundtable discussions.
For more information, please visit: http://www.icvevents.com/.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in Phase II development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck,
and triple-negative breast cancer. In addition to ImmunoPulse™
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse™ platform. For
more information, please visit www.oncosec.com.
Contact
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-icv-manhattan-300186679.html
SOURCE OncoSec Medical Incorporated